Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in the United States
Distribution resumes of first and only medicine to treatplasminogen deficiency type 1
Kedrion Presents Advancements in Ultra-Rare Bleeding Disorders Research
At World Federation of Hemophilia Congress
Kedrion Biopharma Marks Fourth Annual Hereditary Factor 10 Deficiency Day on October 10
Global biopharma company encourages education and awareness around a rare bleeding disorder.
Kedrion stands with the Immunodeficiency community
Our support for patients’ associations worldwide with the objective of improving the life of individuals affected by PIDs
Kedrion Biopharma Supports the Rare Disease Community at the 75th Annual Bleeding Disorders Conference
Kedrion supported the Plasminogen Deficiency Foundation in a roundtable for patients with Congenital Plasminogen Deficiency.
Kedrion Biopharma Announces Support for the Immune Deficiency Foundation Research Grant Program for Second Consecutive Year
The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (PI),
Kedrion confirms its commitment against Rabies infections in the US
Distribution agreement with Kamada for KEDRAB® extended until March 2026
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®
Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®
IPPC 2023: Kedrion alongside PPTA
The Congress brought together policymakers, stakeholders, patient groups and industry in Europe
Kedrion’s global portfolio expands to China to supply human Albumin
This is the first ever approval for a BPL product in China